Bolt Biotherapeutics, Inc.
BOLT
$5.32
$0.050.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.20M | 4.17M | 3.64M | 7.69M | 9.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.20M | 4.17M | 3.64M | 7.69M | 9.78M |
| Cost of Revenue | 34.95M | 42.20M | 50.13M | 56.49M | 61.09M |
| Gross Profit | -29.75M | -38.03M | -46.50M | -48.80M | -51.31M |
| SG&A Expenses | 14.63M | 15.09M | 16.45M | 18.46M | 20.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.89M | 57.60M | 66.90M | 75.93M | 82.11M |
| Operating Income | -44.70M | -53.44M | -63.26M | -68.24M | -72.33M |
| Income Before Tax | -42.68M | -50.71M | -63.35M | -63.12M | -65.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.68 | -50.71 | -63.35 | -63.12 | -65.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.68M | -50.71M | -63.35M | -63.12M | -65.09M |
| EBIT | -44.70M | -53.44M | -63.26M | -68.24M | -72.33M |
| EBITDA | -43.24M | -51.83M | -61.54M | -66.46M | -70.51M |
| EPS Basic | -22.27 | -26.48 | -33.14 | -33.06 | -34.17 |
| Normalized Basic EPS | -13.51 | -16.14 | -19.13 | -20.62 | -21.72 |
| EPS Diluted | -22.27 | -26.48 | -33.14 | -33.06 | -34.17 |
| Normalized Diluted EPS | -13.51 | -16.14 | -19.13 | -20.62 | -21.72 |
| Average Basic Shares Outstanding | 7.67M | 7.66M | 7.65M | 7.64M | 7.62M |
| Average Diluted Shares Outstanding | 7.67M | 7.66M | 7.65M | 7.64M | 7.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |